The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer

Clinical Cancer Research

Volumn 10, Issue 12 II, 2004, Pages

  Perez Soler, Roman ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3042619127     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040017     Document Type: Conference Paper

References (10)

1. Fukuoka M, Yano S, Giaccone G, et al. Final results from a Phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:298.
2. Kris MG, Natale RB, Herbst RS, et al. A Phase II trial of ZD1839 (Iressa) in advanced non-small cell lung cancer patients who had failed plafinum- and docetaxel-based chemotherapy regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:292.
3. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacology study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
4. Perez-Soler R, Chachoua A, Huberman M, et al. Finals results of a Phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (abstract P-611). Lung Cancer 2003;41 (Suppl. 2):S246.
5. Patel JD, Miller VA, Kris MG, et al. Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva TM, OSI-774) in patients with advanced bronchioalveolar (BAC) cell carcinoma. Lung Cancer 2003;41(Suppl.):S56.
6. West HL, Franklin WA, Gumerlock P, et al. ZD 1839 (Iressa) in advanced bronchioalveolar carcinoma (BAC): a preliminary report of SWOG S0126. Lung Cancer 2003;41(Suppl.):S56.
7. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
8. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204.
9. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
10. Clark GM, Perez-Soler R, Siu L, Gordon A, Santabarbara P. Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 2003;22:196.